Citations

Clear

3942 citation(s) found for "To, Van".

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Johnatty, Sharon E. , Kar, Siddhartha , Beesley, Jonathan, Lu, Yi , Gao, Bo , Fasching, Peter A. , Hein, Alexander , Ekici, Arif B. , Beckmann, Matthias W. , Lambrechts, Diether , Nieuwenhuysen, Els Van , Vergote, Ignace , Lambrechts, Sandrina, Rossing, Mary Anne, Chang‐Claude, Jenny , Ness, Roberta B., Moysich, Kirsten B., Levine, Douglas A. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Lubiński, Jan , Jakubowska, Anna , Brinton, Louise A. , Lissowska, Jolanta , Wentzensen, Nicolas , Song, Honglin , Rhenius, Valerie , Campbell, Ian , Eccles, Diana , Sieh, Weiva , Whittemore, Alice S. , McGuire, Valerie , Rothstein, Joseph H. , Sutphen, Rebecca , Gayther, Simon A. , Menon, Usha , Ramus, Susan J. , Pearce, Celeste Leigh, Pike, Malcolm C. , Wu, Anna H. , Kupryjańczyk, Jolanta , Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Śpiewankiewicz, Beata, Goodman, Marc T. , Carney, Michael E., Thompson, Pamela J., Heitz, Florian , Schwaab, Ira, Harter, Philipp , Pisterer, Jacobus, Hillemanns, Peter , Group, on behalf of the AGO Study, Walsh, Christine M. , Lester, Jenny, Oršulić, Sandra , Winham, Stacey J. , Earp, Madalene A. , Fogarty, Zachary C. , Høgdall, Estrid , Jensen, Allan , Cunningham, Julie M. , Vierkant, Robert A. , Schildkraut, Joellen M. , Iversen, Edwin S., Terry, Kathryn L. , Orlow, Irene , Bean, Yukie T., Høgdall, Claus , Lundvall, Lene, McNeish, Iain A. , Paul, James, Carty, Karen , Glasspool, Rosalind , Sellers, Thomas , Kennedy, Catherine J. , Chiew, Yoke-Eng , MacGregor, Stuart , Goode, Ellen L. , DeFazio, Anna , Webb, Penelope M. , Chenevix‐Trench, Georgia , Lambrechts, Diether , Earp, Madalene, Fazio, Anna de , Tyrer, Jonathan P. , Beesley, Jonathan, Doherty, Jennifer A. , Modugno, Francesmary , Gronwald, Jacek , Cybulski, Cezary , Anton‐Culver, Hoda , Ziogas, Argyrios , Gentry‐Maharaj, Aleksandra , Stram, Daniel O. , Wilkens, Lynne R. , Bois, Andreas du , Group, on behalf of the AGO Study, Karlan, Beth Y. , Lester, Jenny, Larson, Melissa C. , Kjær, Susanne K. , Fridley, Brooke L. , Cramer, Daniel W. , Bandera, Elisa V. , Pejovic, Tanja B. , Siddiqui, Nadeem , Berchuck, Andrew , Pharoah, Paul D.P. , Winham, Stacey J , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Moysich, Kirsten , Orlow, Irene , Lissowska, Jolanta , Campbell, Ian G , Glasspool, Rosalind , Kennedy, Catherine J , Fogarty, Zachary C , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Clinical Cancer Research | July 7, 2015 | Volume: 21 | Issue: 23 | Pages: 5264-5276

10.1158/1078-0432.ccr-15-0632 | PMID 26152742 Get It

Abstract Purpose: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. Experimental Design: We analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis. Results: Five SNPs were significantly associated (P ≤ 1.0 × 10−5) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10−6). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤6 × 10−3). Conclusions: We have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies. Clin Cancer Res; 21(23); 5264–76. ©2015 AACR.
CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record
Shirts, Brian H. , Salama, Joseph S , Aronson, Samuel , Gray, Stacy W. , Hindorff, Lucia A. , Jarvik, Gail P. , Tarczy‐Hornoch, Peter , Freimuth, Robert R. , Grundmeier, Robert W. , Hartzler, Andrea L. , Li, Rongling, Peissig, Peggy , Peterson, Josh F. , Rasmussen, Luke V. , Starren, Justin , Overby, Casey Lynnette, Taylor, Casey Overby , Chute, Christopher G. , Chung, Wendy K. , Plon, Sharon E. , Stoffel, Elena M. , Van Allen, Eliezer M , Weck, Karen E. , Williams, Marc S , Jarvik, Gail P , Rasmussen, Luke V , Freimuth, Robert R , Peterson, Josh F , Gray, Stacy W

Mayo Clinic

Journal of the American Medical Informatics Association | July 4, 2015 | Volume: 22 | Issue: 6 | Pages: 1231-1242

10.1093/jamia/ocv065 | PMID 26142422 Get It

Abstract Objective Clinicians’ ability to use and interpret genetic information depends upon how those data are displayed in electronic health records (EHRs). There is a critical need to develop systems to effectively display genetic information in EHRs and augment clinical decision support (CDS). Materials and Methods The National Institutes of Health (NIH)-sponsored Clinical Sequencing Exploratory Research and Electronic Medical Records & Genomics EHR Working Groups conducted a multiphase, iterative process involving working group discussions and 2 surveys in order to determine how genetic and genomic information are currently displayed in EHRs, envision optimal uses for different types of genetic or genomic information, and prioritize areas for EHR improvement. Results There is substantial heterogeneity in how genetic information enters and is documented in EHR systems. Most institutions indicated that genetic information was displayed in multiple locations in their EHRs. Among surveyed institutions, genetic information enters the EHR through multiple laboratory sources and through clinician notes. For laboratory-based data, the source laboratory was the main determinant of the location of genetic information in the EHR. The highest priority recommendation was to address the need to implement CDS mechanisms and content for decision support for medically actionable genetic information. Conclusion Heterogeneity of genetic information flow and importance of source laboratory, rather than clinical content, as a determinant of information representation are major barriers to using genetic information optimally in patient care. Greater effort to develop interoperable systems to receive and consistently display genetic and/or genomic information and alert clinicians to genomic-dependent improvements to clinical care is recommended.
The Changing Landscape of Vestibular Schwannoma Management in the United States—A Shift Toward Conservatism
Carlson, Matthew L. , Habermann, Elizabeth B. , Wagie, Amy E., Driscoll, Colin L. W., Jacob, Jeffrey T. , Link, Michael J. , Driscoll, Colin L., Van Gompel, Jamie J, Gompel, Jamie J. Van , Habermann, Elizabeth

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 1, 2015 | Volume: 153 | Issue: 3 | Pages: 440-446

10.1177/0194599815590105 | PMID 26129740 Get It

ObjectiveTo characterize the evolving management of vestibular schwannoma (VS) in the United States.Study DesignRetrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database.SettingSEER database.Subjects and MethodsAll patients with a diagnosis of VS were analyzed. Data were described and compared using trend analyses and univariate and multivariable logistic regression.ResultsA total of 8330 patients (average age 54.7 years, 51.9% female) were analyzed. The mean incidence was approximately 1.1 per 100,000 per year and did not vary significantly across time; however, from 2004 to 2011, there was a statistically significant decrease in tumor size category at time of diagnosis (P <. 01). Overall, 3982 patients (48%) received primary microsurgery, 1978 (24%) radiation therapy alone, and 2370 (29%) observation. Within the microsurgical cohort, 732 (18%) underwent subtotal resection, and of those, 98 (13.4%) received postoperative radiation therapy. Multivariable regression revealed that surgical treatment was more common in younger patients and larger tumor size categories (P <. 05). Management trend analysis revealed that microsurgery was used less frequently over time (P <. 0001), observation was used more frequently (P <. 0001), and the pattern of radiation therapy remained unchanged. Linear regression was used to create an equation that was applied to predict future management practices. These data predict that by 2026, half of all cases of VS will be managed initially with observation.ConclusionWhile the incidence of VS has remained steady, tumor size at time of diagnosis has decreased over time. Within the United States there has been a clear, recent evolution in management toward observation.
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein, Alexander , Lambrechts, Diether , Minckwitz, Gϋnter von, Häberle, Lothar , Eidtmann, Holger, Tesch, Hans , Hilfrich, J., Schem, Christian , Rezai, Mahdi , Gerber, Bernd, Costa, Serban Dan, Blohmer, Jens‐Uwe , Schwedler, Kathrin, Kittel, K., Fehm, Tanja , Kunz, Georg , Beckmann, Matthias W. , Ekici, Arif B. , Hanusch, Claus , Huober, Jens , Liedtke, Cornelia, Moisse, Matthieu , Müller, Volkmar , Nekljudova, Valentina , Peuteman, Gilian, Rack, Brigitte , Rübner, Matthias, Brussel, Thomas Van , Wang, Liewei , Weinshilboum, Richard M. , Loibl, Sibylle , Fasching, Peter A. , Lambrechts, Diether , Untch, Michael , Mau, Christine , Weinshilboum, Richard M. , Lambrechts, Diether , Hein, Alexander , Lambrechts, Diether , Ekici, Arif B , Moisse, Matthieu , Fehm, Tanja

Mayo Clinic

International Journal of Cancer | June 23, 2015 | Volume: 137 | Issue: 12 | Pages: 2981-2988

10.1002/ijc.29656 | PMID 26100253 Get It

Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different effects on progression‐free and overall survival, suggesting that a subgroup of patients may benefit from this treatment. Unfortunately, no biomarkers exist to identify these patients. Here, we investigate whether single nucleotide polymorphisms (SNPs) in VEGF pathway genes correlate with pathological complete response (pCR) in the neoadjuvant GeparQuinto trial. HER2‐negative patients were randomized into treatment arms receiving either BEV combined with standard chemotherapy or chemotherapy alone. In a pre‐planned biomarker study, DNA was collected from 729 and 724 patients, respectively from both treatment arms, and genotyped for 125 SNPs. Logistic regression assessed interaction between individual SNPs and both treatment arms to predict pCR. Five SNPs may be associated with a better response to BEV, but none of them remained significant after correction for multiple testing. The two SNPs most strongly associated, rs833058 and rs699947, were located upstream of the VEGF‐A promoter. Odds ratios for the homozygous common, heterozygous and homozygous rare rs833058 genotypes were 2.36 (95% CI, 1.49–3.75), 1.20 (95% CI, 0.88–1.64) and 0.61 (95% CI, 0.34–1.12). Notably, some SNPs in VEGF‐A exhibited a more pronounced effect in the triple‐negative subgroup. Several SNPs in VEGF‐A may be associated with improved pCR when receiving BEV in the neoadjuvant setting. Although none of the observed effects survived correction for multiple testing, our observations are consistent with previous studies on BEV efficacy in BC. Further research is warranted to clarify the predictive value of these markers.
Memory, executive, and multidomain subtle cognitive impairment
Toledo, Jon B. , Bjerke, Maria , Rozycki, Martin, Jack, Clifford R. , Weiner, Michael W. , Arnold, Steven E. , Reiman, Eric M. , Davatzikos, Christos , Shaw, Leslie M. , Trojanowski, John Q. , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Aisen, Paul , Weiner, Michael, Petersen, Ronald, Jagust, William, Trojanowki, John Q., Green, Robert C., Saykin, Andrew J., Liu, Enchi , Green, Robert C., Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , DeCarli, Charles, Jagust, William, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald, Johnson, Kris , Doody, Rachelle S., Chowdhury, Munir , Bell, Karen L. , Leon, Sue, Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varon, Daniel, Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E., Karlawish, Jason , Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A. , Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Saykin, Andrew J., Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John, Kertesz, Andrew, Drost, Dick, Hernando, Raymundo, Sarrael, Antero, Schultz, Susan K. , Ponto, Laura L. Boles , Shim, Hyungsub , Smith, Karen E. , Relkin, Norman , Chaing, Gloria, Raudin, Lisa, Smith, Amanda , Fargher, Kristin, Raj, Balebail Ashok, Chen, Kewei , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Weiner, Michael, Petersen, Ronald, Jagust, William, Toga, Arthur W. , Beckett, Laurel , Green, Robert C., Saykin, Andrew J., Morris, John C. , Green, Robert C., Petersen, Ronald, Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jagust, William, Koeppe, Robert A. , Foster, Norm, Reiman, Eric M., Mathis, Chet, Lee, Virginia M.‐Y. , Saykin, Andrew J. , Foroud, Tatiana , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Petersen, Ronald, Villanueva-Meyer, Javier E. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Varón, Daniel , Rusinek, Henry , Leon, Mony J. de , Arnold, Steven E., Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Stefanovic, Bojana , Feldman, Howard , Kertesz, Andrew, Rogers, John, Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Saykin, Andrew J., Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Rogers, John, Kertesz, Andrew, Jack, Clifford R , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | June 18, 2015 | Volume: 85 | Issue: 2 | Pages: 144-153

10.1212/wnl.0000000000001738 | PMID 26085606 Get It

Functional neuroimaging correlates of thinking flexibility and knowledge structure in memory: Exploring the relationships between clinical reasoning and diagnostic thinking
Durning, Steven J. , Costanzo, Michelle E. , Beckman, Thomas J. , Artino, Anthony R. , Roy, Michael J. , Vleuten, Cees van der , Holmboe, Eric S. , Lipner, Rebecca S. , Schuwirth, Lambert

Mayo Clinic

Medical Teacher | June 16, 2015 | Volume: 38 | Issue: 6 | Pages: 570-577

10.3109/0142159x.2015.1047755 | PMID 26079668 Get It

C‐ing the Genome: A Compendium of Chromosome Conformation Capture Methods to Study Higher‐Order Chromatin Organization
Barutcu, A. Rasim , Fritz, Andrew J. , Zaidi, Sayyed K. , Wijnen, André J. van , Lian, Jane B. , Stein, Janet L. , Nickerson, Jeffrey A. , Imbalzano, Anthony N. , van Wijnen, Andre J, Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | June 9, 2015 | Volume: 231 | Issue: 1 | Pages: 31-35

10.1002/jcp.25062 | PMID 26059817 Get It

Three‐dimensional organization of the chromatin has important roles in transcription, replication, DNA repair, and pathologic events such as translocations. There are two fundamental ways to study higher‐order chromatin organization: microscopic and molecular approaches. In this review, we briefly introduce the molecular approaches, focusing on chromosome conformation capture or “3C” technology and its derivatives, which can be used to probe chromatin folding at resolutions beyond that provided by microscopy techniques. We further discuss the different types of data generated by the 3C‐based methods and how they can be used to answer distinct biological questions. J. Cell. Physiol. 230: 31–35, 2016. © 2015 Wiley Periodicals, Inc.
A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences
Hoffmann, Thomas J. , Jorgenson, Eric , Habel, Laurel A. , Passarelli, Michael N. , Cario, Clinton L. , Emami, Nima C. , Chao, Chun , Ghai, Nirupa R. , Shan, Jun , Ranatunga, Dilrini K., Aaronson, David S., Presti, Joseph C. , Berndt, Sonja I. , McDonnell, Shannon K. , French, Amy J. , Schaid, Daniel J. , Thibodeau, Stephen N. , Freedman, Matthew L. , Mucci, Lorelei A. , Haiman, Christopher A. , Henderson, Brian E., Seminara, Daniela, Kvale, Mark , Schaefer, Catherine , Risch, Neil , Witte, John S. , Wang, Zhaoming , Van Den Eeden, Stephen K , Sakoda, Lori C. , Graff, Rebecca E. , Quesenberry, Charles P. , Wang, Zhaoming , Chanock, Stephen Jacob , Li, Qiyuan , Penney, Kathryn , Kwok, Pui–Yan , Wang, Zhaoming , McDonnell, Shannon K

Mayo Clinic

Cancer Discovery | June 2, 2015 | Volume: 5 | Issue: 8 | Pages: 878-891

10.1158/2159-8290.cd-15-0315 | PMID 26034056 Get It

Abstract A genome-wide association study (GWAS) of prostate cancer in Kaiser Permanente health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) revealed a new independent risk indel rs4646284 at the previously identified locus 6q25.3 that replicated in PEGASUS (N = 7,539) and the Multiethnic Cohort (N = 4,679) with an overall P = 1.0 × 10−19 (OR, 1.18). Across the 6q25.3 locus, rs4646284 exhibited the strongest association with expression of SLC22A1 (P = 1.3 × 10−23) and SLC22A3 (P = 3.2 × 10−52). At the known 19q13.33 locus, rs2659124 (P = 1.3 × 10−13; OR, 1.18) nominally replicated in PEGASUS. A risk score of 105 known risk SNPs was strongly associated with prostate cancer (P &lt; 1.0 × 10−8). Comparing the highest to lowest risk score deciles, the OR was 6.22 for non-Hispanic whites, 5.82 for Latinos, 3.77 for African-Americans, and 3.38 for East Asians. In non-Hispanic whites, the 105 risk SNPs explained approximately 7.6% of disease heritability. The entire GWAS array explained approximately 33.4% of heritability, with a 4.3-fold enrichment within DNaseI hypersensitivity sites (P = 0.004). Significance: Taken together, our findings of independent risk variants, ethnic variation in existing SNP replication, and remaining unexplained heritability have important implications for further clarifying the genetic risk of prostate cancer. Our findings also suggest that there may be much promise in evaluating understudied variation, such as indels and ethnically diverse populations. Cancer Discov; 5(8); 878–91. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 783
Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification
Escalante, Patricio , Peikert, Tobias, Keulen, Virginia P. Van , Erskine, Courtney L. , Bornhorst, Cathy L., Andrist, Boleyn R., McCoy, Kevin , Pease, Larry R. , Abraham, Roshini S. , Knutson, Keith L. , Kita, Hirohito , Schrum, Adam G. , Knutson, Keith L. , Limper, Andrew H. , Kita, H , Schrum, Adam G

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 1, 2015 | Volume: 192 | Issue: 5 | Pages: 605-617

10.1164/rccm.201412-2141oc | PMID 26030344 Get It

Abstract Rationale Most immunocompetent patients diagnosed with latent tuberculosis infection (LTBI) will not progress to tuberculosis (TB) reactivation. However, current diagnostic tools cannot reliably distinguish nonprogressing from progressing patients a priori, and thus LTBI therapy must be prescribed with suboptimal patient specificity. We hypothesized that LTBI diagnostics could be improved by generating immunomarker profiles capable of categorizing distinct patient subsets by a combinatorial immunoassay approach. Objectives A combinatorial immunoassay analysis was applied to identify potential immunomarker combinations that distinguish among unexposed subjects, untreated patients with LTBI, and treated patients with LTBI and to differentiate risk of reactivation. Methods IFN-γ release assay (IGRA) was combined with a flow cytometric assay that detects induction of CD25+CD134+ coexpression on TB antigen–stimulated T cells from peripheral blood. The combinatorial immunoassay analysis was based on receiver operating characteristic curves, technical cut-offs, 95% bivariate normal density ellipse prediction, and statistical analysis. Risk of reactivation was estimated with a prediction formula. Measurements and Main Results Sixty-five out of 150 subjects were included. The combinatorial immunoassay approach identified at least four different T-cell subsets. The representation of these immune phenotypes was more heterogeneous in untreated patients with LTBI than in treated patients with LTBI or unexposed groups. Patients with IGRA(+) CD4+CD25+CD134+ T-cell phenotypes had the highest estimated reactivation risk (4.11 ± 2.11%). Conclusions These findings suggest that immune phenotypes defined by combinatorial assays may potentially have a role in identifying those at risk of developing TB; this potential role is supported by risk of reactivation modeling. Prospective studies will be needed to test this novel approach.